NeuroSense Therapeutics Ltd.
NRSN · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Market Cap | $48,010 | $23,621 | $25,981 | $25,157 |
| - Cash | $666 | $666 | $3,378 | $344 |
| + Debt | $0 | $0 | $73 | $19 |
| Enterprise Value | $47,344 | $22,955 | $22,676 | $24,832 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$2,342 | -$2,342 | -$1,766 | -$2,102 |
| % Margin | – | – | – | – |
| Net Income | -$2,355 | -$2,355 | -$1,801 | -$2,148 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.093 | -0.093 | -0.083 | -0.11 |
| % Growth | 0% | -11.4% | 24.4% | – |
| Operating Cash Flow | -$2 | $0 | $0 | $0 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$2 | $0 | $0 | $0 |